HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Problems and strategies for bone marrow transplantation in acute leukemia and chronic myelogenous leukemia.

AbstractCertain marrow transplant protocols can now result in a 50-70% long disease-free survival and low relapse rates in acute leukemia (AL) in CR1, CR2, or CML following cytoreduction and HLA-identical marrow infusion. Two-thirds of deaths are due to acute and chronic graft-versus-host disease (GVHD) or viral infection. The other deaths are due to toxicities of the cytoreductive treatment. Prevention of GVHD has been tried by treatment after the transplant or treating the marrow (lymphocyte depletion). Cyclosporine (CsA) or CsA plus methotrexate has reduced acute GVHD but not chronic GVHD. Marrow has been treated with monoclonal antibodies and lectins or elutriated to decrease numbers of T lymphocytes. Some studies have been effective, but the majority have shown an increased number of rejections or leukemic relapses. Apart from teratogenic effects, thalidomide has minimal toxicity. It effectively prevents and treats acute and chronic GVHD in rodent models. Clinical trials will soon begin. Mismatched related or matched unrelated donors have been employed in the clinic with limited success. Alternatively, autologous transplantation in acute leukemia has shown promising results. Possible solutions to remaining problems and strategies will be discussed.
AuthorsG W Santos (Affiliation: Johns Hopkins Oncology Center, Baltimore, MD 21205.)
JournalCancer detection and prevention (Cancer Detect Prev) Vol. 12 Issue 1-6 Pg. 589-96 ( 1988) ISSN: 0361-090X [Print] UNITED STATES
PMID3052840 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Cyclosporins
  • Methotrexate
Topics
  • Acute Disease
  • Bone Marrow Transplantation
  • Cyclosporins (therapeutic use)
  • Graft vs Host Disease (prevention & control)
  • Humans
  • Leukemia (therapy)
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy)
  • Methotrexate (therapeutic use)
  • Transplantation Immunology
  • Virus Diseases (complications, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD